Related Experiment Video

Updated: Jun 5, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Targeted therapies in metastatic melanoma: toward a clinical breakthrough?

Fanny Julia1, Luc Thomas, Charles Dumontet

  • 1Centre de Recherche en Cancérologie de Lyon,Faculté de Médecine Rockefeller, 8 Avenue Rockefeller, 69008 Lyon, France.

Anti-Cancer Agents in Medicinal Chemistry
|January 18, 2011
PubMed

Insights

New targeted therapies show promise for metastatic melanoma, offering alternatives to dacarbazine. Ipilimumab and BRAF inhibitors are effective, with ongoing trials for other agents.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Metastatic melanoma is an aggressive cancer with dacarbazine as a long-standing standard therapy.
  • Advances in understanding melanoma cell signaling and immune responses have led to novel therapeutic strategies.
  • The efficacy of new treatments requires validation through extensive clinical trials.

Purpose of the Study:

  • To review the latest developments in targeted therapies for metastatic melanoma.
  • To discuss the current perspectives on managing metastatic melanoma with novel agents.
  • To highlight the clinical significance of emerging molecular targets and immunotherapies.

Main Methods:

  • Literature review of recent clinical trials and published data.
  • Analysis of the efficacy and safety profiles of new therapeutic molecules.
  • Synthesis of information on targeted agents, including BRAF, MEK, c-KIT inhibitors, and ipilimumab.

Main Results:

  • Ipilimumab (anti-CTLA4 monoclonal antibody) and V600-E-BRAF inhibitors demonstrate encouraging results in metastatic melanoma treatment.
  • c-KIT and MEK inhibitors are currently under evaluation, indicating ongoing research and development.
  • These new therapies represent a shift from traditional chemotherapy towards personalized medicine.

Conclusions:

  • Emerging targeted therapies and immunotherapies are transforming metastatic melanoma management.
  • Further clinical trials are essential to confirm the long-term efficacy and safety of these novel agents.
  • The future of metastatic melanoma treatment lies in a combination of molecularly targeted drugs and immunomodulatory approaches.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...